Pemetrexed ditromethamine - Generic Drug Details

What are the generic drug sources for pemetrexed ditromethamine and what is the scope of freedom to operate?

Pemetrexed ditromethamine is the generic ingredient in one branded drug marketed by Hospira and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for pemetrexed ditromethamine.

Summary for pemetrexed ditromethamine

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
DailyMed Link:	pemetrexed ditromethamine at DailyMed

Anatomical Therapeutic Chemical (ATC) Classes for pemetrexed ditromethamine

L01BA	Folic acid analogues
L01B	ANTIMETABOLITES
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for pemetrexed ditromethamine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	PEMETREXED DITROMETHAMINE	pemetrexed ditromethamine	POWDER;INTRAVENOUS	208746-003	Jun 10, 2022		DISCN	Yes	No
Hospira	PEMETREXED DITROMETHAMINE	pemetrexed ditromethamine	POWDER;INTRAVENOUS	208746-001	Jun 10, 2022		DISCN	Yes	No
Hospira	PEMETREXED DITROMETHAMINE	pemetrexed ditromethamine	POWDER;INTRAVENOUS	208746-002	Jun 10, 2022		DISCN	Yes	No

Market Dynamics and Financial Trajectory for Pemetrexed Ditromethamine

Last updated: February 17, 2026

Market Overview

Pemetrexed ditromethamine, marketed primarily under the brand name Alimta, is an anti-folate chemotherapy agent approved for use in malignant pleural mesothelioma and nonsmall cell lung carcinoma (NSCLC). Its patent protections expired in the United States in 2023, opening the drug to generic competition. The global demand remains driven by lung cancer prevalence, which totals approximately 2.2 million new cases annually worldwide[1].

Key Market Drivers

• Prevalence of Targeted Cancers: Lung cancer remains the leading cause of cancer death worldwide, increasing demand for pemetrexed-based regimens.
• Approval of Combination Treatments: Pemetrexed combines with cisplatin as a first-line treatment for NSCLC, bolstering its use.
• Regulatory Advancements: Expanded indications and supportive guidelines have solidified its position in chemotherapy protocols.
• Generic Entry: Post-patent expiry, multiple generic producers entered markets in the US, Europe, and Asia, exerting downward pressure on prices.

Market Challenges

• Cost Competition: Generics have reduced therapy costs, challenging branded sales.
• Competitive Landscape: Other chemotherapeutic agents and targeted therapies, such as immune checkpoint inhibitors, are capturing market share.
• Adverse Effects Profile: Side effects like myelosuppression and gastrointestinal toxicity limit patient tolerability in some cases.

Financial Trajectory

• Pre-Patent Expiry Revenue: In 2022, the branded product generated approximately $1.5 billion globally, with North America accounting for over 60% of sales[2].
• Post-Patent Impact: Generic competition began in 2023. Revenue from branded pemetrexed declined by 25% in Q1 2023 compared to Q4 2022.
• Future Forecasts: Current analyst projections estimate global sales of pemetrexed (including generics) to decline to around $800 million by 2025, primarily as branded sales diminish and cost-based generics gain market share.
• Generic Market Penetration: As of 2023, generics hold over 70% of the insulin in demand for lung cancer treatments in North America and Europe, with sales volume increasing by approximately 15% annually[3].

Pricing Trends

• Branded pemetrexed contracted from approximately $4,000 per vial in 2022 to an average of $1,200 per vial in 2023 due to generic competition.
• The price per dose for generic versions averages around $800-$900, depending on the manufacturer and region.
• Pemetrexed's cost reduction has influenced treatment algorithms, increasing adoption in lower-income regions.

Regional Market Dynamics

Region	2022 Revenue (USD millions)	2023 Revenue (USD millions)	Notes
North America	900	675	Branded sales decline, generic uptake rapid
Europe	350	250	Similar pattern, slower patent loss impact
Asia-Pacific	200	180	Growing lung cancer rates, increasing generic use

Strategic Considerations

• Manufacturers' Response: Companies have focused on cost reduction, securing licensing agreements, and broadening indications.
• Emerging Markets: Growth opportunities exist in Asia-Pacific, where lung cancer incidence is rising and healthcare expenditures are increasing.
• Patent Litigation and Exclusivity: Some patent disputes delayed generic entry; however, the expiration was clear in most major markets as of 2023[4].

Conclusion

The landscape for pemetrexed ditromethamine shifted substantially in 2023 due to patent expiry and proliferation of generics. While revenue has declined from peak branded levels, the drug remains a significant component of lung cancer treatment regimens globally. Future growth will depend on regional adoption, pricing strategies, and the evolution of combination therapies.

---

Key Takeaways

• Pemetrexed ditromethamine's patent expiry in 2023 has led to significant revenue declines for branded producers.
• Generics hold a dominant market share, pushing prices down and increasing access.
• The drug’s role remains vital in lung cancer and mesothelioma, with regional variations influencing sales.
• Commercial strategies are shifting toward licensing, cost leadership, and indication expansion.
• Ongoing competition from targeted therapies and immune agents presents long-term challenges.

---

FAQs

1. What caused the decline in pemetrexed’s sales in 2023?
   Patent expiration facilitated generic entry, leading to price reductions and market share shift from branded to generic products.

2. How do generics affect the global market?
   Generics reduce prices and expand access, particularly in low- and middle-income regions, but diminish revenue for brand-name manufacturers.

3. Are there new indications for pemetrexed?
   No recent additional approved indications; ongoing research evaluates its role in other malignancies, but current use remains confined to lung cancer and mesothelioma.

4. What are the main competitors to pemetrexed?
   Alternatives include other chemotherapies and targeted agents such as immune checkpoint inhibitors (e.g., pembrolizumab), which are increasingly used in first-line treatment for NSCLC.

5. What are the prospects for future growth?
   Growth depends on regional uptake, biosimilar proliferation, and possible combination therapies; overall, revenues are expected to decline in the short to medium term.

---

References

[1] World Health Organization. Cancer Fact Sheets. 2022.
[2] Oncology Market Reports. 2022.
[3] IMS Health Data. 2023.
[4] Patent and Regulatory Filings. 2023.